Defendant
3 cases as defendant.
I'll verify the company's profile with web searches.
Let me verify the current corporate status of West-Ward and Hikma's size.
Company overview. "West-Ward" refers to West-Ward Pharmaceuticals Corp., a U.S. generic-drug manufacturer headquartered in Eatontown, New Jersey. It is a wholly owned subsidiary of Hikma Pharmaceuticals PLC (LSE: HIK; NASDAQ Dubai: HIK), the London-headquartered multinational founded in 1978 in Jordan. Hikma acquired West-Ward in 1991; in June 2018 the U.S. subsidiary was rebranded as Hikma Pharmaceuticals USA Inc., with the West-Ward name retained on some product labeling during the transition. Hikma's group revenue was roughly $3 billion in 2024 with about 9,000–9,500 employees worldwide, of whom roughly 2,000 were U.S.-based at the time of the rebrand. West-Ward itself does not file separate financials.
Products / operations. West-Ward is an operating generics manufacturer and contract manufacturer, not an NPE. It develops, manufactures and markets prescription generic and branded generics across oral solid, liquid, inhalant and sterile injectable dosage forms, including controlled-release and DEA-scheduled products, oncology/cytotoxic injectables and aseptic vials, ampoules and IV bags. It sells to wholesalers, distributors, chains, health systems and government agencies, and supplies CMO clients. Growth came through acquisition: Baxter's U.S. generic injectables business (Cherry Hill, NJ; Memphis, TN) in 2011 for about $112 million, and Boehringer Ingelheim's Roxane Laboratories generics business (including the Columbus, Ohio solid-dose plant) in 2016 for roughly $1.5 billion.
Litigation posture. West-Ward appears only as a defendant (3 of 3 tracked cases; 0 as plaintiff), consistent with an operating company targeted by brand manufacturers rather than an assertion entity. Its cases cluster in New Jersey and New York (D.N.J. and E.D.N.Y.), not in plaintiff-friendly venues such as the Eastern District of Texas.
Notable cases. Two tracked suits are Jazz Pharmaceuticals' Hatch-Waxman actions against Roxane Laboratories/West-Ward over generic Xyrem (sodium oxybate) in D.N.J., beginning with Roxane's 2010 ANDA and first-filer Paragraph IV certification; the parties settled in April 2017, giving Hikma/West-Ward authorized-generic rights from January 2023 plus a license under the Roxane ANDA. The third is UFCW Local 1500 Welfare Fund v. Jazz Pharmaceuticals (E.D.N.Y., 2020), an antitrust class action naming West-Ward among the Roxane/Hikma defendants over that settlement; related end-payor suits were consolidated into an N.D. Cal. MDL.
Class action antitrust suit by UFCW Local 1500 Welfare Fund against Jazz and others in E.D.N.Y. It alleges the '106 patent was improperly listed in the Orange Book and invalid.
Jazz sued Roxane Laboratories (later Hikma/West-Ward) asserting the '650 patent. The case was consolidated with 2:10-cv-06108 and 2:12-cv-07459 in April 2013, and the consolidated case settled April 5, 2017, granting Hikma/West-Ward an authorized generic of Xyrem beginning Jan. 1, 2023.
Lead consolidated Hatch-Waxman action over Xyrem sodium oxybate. The ’506 patent was among the original patents-in-suit, along with the ’431, ’889, ’219, ’059, and the ’730 family. Resolved by settlement with no final judgment on the ’506 patent.